Atrial fibrillation recurrence after initial long-term success of catheter ablation has been described, yet not well studied. We assessed the electrophysiological findings and outcomes of repeat ablation procedures in this setting.
A trial fibrillation (AF) is the most common tachyarrhythmia in clinical practice and has been associated with increased morbidity and mortality. 1 Catheter-based pulmonary vein (PV) isolation is a wellestablished treatment strategy for drug-refractory AF and an acceptable first-line therapy in paroxysmal AF. 2, 3 Long-term success of AF ablation procedures, defined as freedom from arrhythmia recurrence for a minimum of 36 months off antiarrhythmic therapy, can be achieved in many patients. 4, 5 Although most arrhythmia recurrences typically occur in the first 6 months to 1 year after ablation, [5] [6] [7] AF recurrences, after initially achieving long-term success, have been reported. In the setting of early recurrences, reconnection of one or more of the previously ablated PV has been frequently described 5, 8 and repeat ablations provided incremental benefit for rhythm control. 5 However, little is known about the electrophysiological characteristics and outcomes of repeat ablations in patients with initial long-term success and very late arrhythmia recurrences. More specifically, little is known about PV reconnection rates in this setting and non-PV ablation targets, especially in patients in whom the PVs had remained isolated from prior ablation. In today's clinical practice, electrophysiologists often face such scenarios which represent both clinical and procedural challenges.
In this study, we aim to describe the electrophysiological findings and outcomes of repeat ablation procedures in patients with recurrent arrhythmia after initial long-term success of AF ablation.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
All consecutive patients who underwent AF ablation at our institution between January 2000 and December 2015 were enrolled in a prospectively maintained data registry. From this registry, we only included patients who had AF recurrence after initially achieving long-term success with ≥1 ablation procedures, then underwent repeat ablation for recurrent arrhythmia. We defined long-term success as freedom from AF recurrence beyond the 3-month blanking period, for a minimum of 36 months from the date of the last ablation procedure. Patients who required either electric cardioversion or antiarrhythmic drug therapy to achieve freedom from arrhythmia beyond the blanking period and before 36 months post-ablation were excluded. A total of
WHAT IS KNOWN?
• Arrhythmia recurrences after atrial fibrillation ablation procedures remain problematic.
• In the setting of early recurrences after atrial fibrillation ablation, reconnection of one or more of the previously ablated pulmonary veins is thought to be the culprit and repeat ablations provided incremental benefit for rhythm control.
WHAT THE STUDY ADDS?
• Pulmonary vein reconnection is the most common electrophysiological finding in patients with atrial fibrillation recurrence after initial long-term success (defined as ≥36 months without antiarrhythmics use), but with lower rates than what has been reported for early recurrences.
• Repeat ablations in the setting of atrial fibrillation recurrence after long-term ablation success involve complex ablation approaches to reisolate the pulmonary veins, extend antral ablations, and modify the atrial substrate and are associated with acceptable success rates.
3 137 patients met our inclusion criteria. The study protocol was approved by Cleveland Clinic institutional review board.
Radiofrequency Ablation Protocol
Our AF ablation protocol and periprocedural anticoagulation strategies were described previously in detail. 9, 10 Antiarrhythmics were stopped 4 to 5 half-lives before ablation whenever possible and depending on the clinical scenario. All patients were therapeutically anticoagulated when they underwent the ablation procedure. An intravascular ultrasound placed in the right atrium was used to assist in performing trans-septal puncture, to guide catheter manipulation and assess for catheter-tissue contact during ablation, and was to monitor for complications during the procedure. A circular mapping catheter (Lasso) was used to assess PV antral potentials and to guide both PV and non-PV ablations to ensure continuity of the ablation lines and absence of gaps. The ablation procedures targeted mainly reisolation of PVs where conduction recovery was detected, as well as substrate modification which included the posterior wall, septal to the right PVs, roof, appendage, coronary sinus, superior vena cava, in addition to left atrial flutter (AFL) ablations when clinically applicable and at the discretion of the operator. In superior vena cava ablations, pacing and assessment for phrenic nerve stimulation was performed before any ablation energy application.
The decision to perform mapping and ablation in sinus rhythm after electric cardioversion or in AF was up to the operator. Patients who remained in AF after ablation underwent electric cardioversion to sinus rhythm followed by confirmation of isolation of the PVs and adequate ablation of non-PV targets. Additional ablation in sinus rhythm was performed when needed.
In patients in whom the PVs were found to have remained isolated from prior ablations, isoproterenol infusion up to 20 μg/min and up to 10 minutes was used to assess for non-PV triggers and these were targeted with ablation. Blood pressure was closely monitored during infusions, and isoproterenol was stopped when a severe hypotensive response occurred.
For all patients with a history of typical AFL, a cavotricuspid isthmus line was performed with confirmation of bidirectional block as an end point.
Post-Ablation Follow-Up Protocol
In all patients, clinical data were collected before the ablation procedures, during follow-up visits, and from all other forms of encounters with the patients or their referring physicians, including telephone calls and clinical letters, and continuously updated using our institution's electronic medical records. Post-ablation, patients were usually hospitalized overnight and discharged on the following day, whenever appropriate. Clinical follow-up visits and 12-lead ECG were scheduled at 3, 6, and 12 months post-procedure and on a yearly basis thereafter. More frequent follow-up visits were scheduled as needed for patients with recurrent arrhythmia and for those who had symptoms or required close management of their long-term anticoagulation. All patients were provided with rhythm transmitters and were instructed to send transtelephonic ECG transmissions on a weekly basis and whenever symptomatic for a minimum of 3 months after the procedure. Additional event monitoring was obtained beyond the 3-month period for patients with documented arrhythmia and those who developed symptoms suggestive of arrhythmia during this time period. Holter monitor recordings were obtained in patients who were suspected to have arrhythmia recurrences but had no electrocardiographic documentation. Interrogation of implanted devices, whenever available, was also used to assess for arrhythmia recurrence. Recurrence was defined as an episode of atrial arrhythmia beyond the first 3 months post-ablation (blanking period), lasting for 30 s or more, documented on 12-lead ECG, event or Holter monitor, or during interrogation of implanted devices.
Antiarrhythmic medications were typically prescribed for 3 months post-ablation (during the blanking period). Patients were generally taken off antiarrhythmic medications after success of redo ablations, but in some situations in a shared medical decision process, these were continued and no attempts were made to discontinue them when patients were doing clinically well without documented arrhythmia beyond the blanking period. For those who continued to have recurrences, either antiarrhythmic or additional ablation procedures were offered.
Clinical Outcomes
The outcomes of interest were assessed for redo ablations performed after initial long-term success of AF ablation procedures. The findings and outcomes of interest were (1) the electrophysiological findings during the first ablation after long-term success and (2) success at last follow-up, with one or multiple ablations, defined as freedom from arrhythmia recurrence.
Statistical Analysis
All descriptive statistics were obtained by using the statistical software JMP pro version 10.0 (SAS, NC). Continuous variables are presented as mean values and SD or median and quartiles, as appropriate. Categorical variables are presented as n (%).
RESULTS
Between 2000 and 2015, 10 378 patients underwent AF ablation procedures at our institution, of which 137 had repeat ablation for AF recurrence after achieving long-term success, and were included in this study.
The baseline characteristics of the study population are shown in Table. The mean age was 63.5±8.8 years, and 73% were male patients. The median arrhythmiafree period after initial ablation, which defined longterm success, was 52 months (41-68 months). The latter was achieved after 1, 2, or 3 prior ablations in 101 (74%), 28 (20%), and 8 (6%) patients, respectively. The targeted AF was persistent in 42.3% and paroxysmal AF in 57.7% of them. Our initial ablation strategy typically involves antral PV isolation with a lasso-guided approach, and in most patients, especially those with persistent AF, posterior wall ablation. In 36 patients, >1 ablation procedure was initially required to achieve longterm success. In these additional ablation procedures, PV antral ablations targeted areas of electric recovery at the left superior, left inferior, right superior, and right inferior PVs in 32 (88.9%), 27 (75%), 28 (77.7%), and 32 (88.9%) patients, respectively. Additional ablations to the superior vena cava, posterior wall, inferior to right PVs, coronary sinus, and cavotricuspid isthmus were performed in 21 (58%), 12 (33%), 7 (19%), 2 (6%), 4 (11%), and 9 (25%) patients, respectively.
Electrophysiological Findings During Redo Ablation After Initial Long-Term Ablation Success
Out of 137 patients who underwent redo ablation procedures after initial long-term AF ablation success, 67.1% presented in sinus rhythm on the day of repeat ablation, whereas 23.3% presented in AF, 7.3% in AFL, and the remaining 1.4% in atrially paced rhythm (Table) . During the ablation procedure after initial longterm success, reconnection along the antra of at least one of the previously ablated PVs was found in 111 (81%) patients. Reconnection along a left superior, left inferior, left common, right superior, right inferior, and right common PV was found in 88 (64%), 85 (62%), 18 (13%), 69 (50%), 74 (54%), and 4 (2.9%) patients, respectively. Additional non-PV ablations were performed in 127 (92.7%) patients and were as follows: posterior wall (46%), septal to right PVs (49%), inferior to right PVs (34%), superior vena cava (35%), coronary sinus (16%), left atrial appendage (15%) and lines at the roof (52%), left inferior PV to mitral annulus (15%), right superior PV to mitral annulus (10%), and cavotricuspid isthmus ablation (33%; Figure 1) .
In patients without any PV reconnections (19%), ablations were performed at the posterior wall (30.8%), roof (53.8%), inferior to right inferior PV (26.9%), septal to right PV (42.3%), coronary sinus (7.7%), left inferior PV to mitral annulus (26.9%), right superior PV to mitral annulus (15.4%), left atrial appendage (23%), and cavotricuspid isthmus (46%; Figure 2 ).
Outcomes of Repeat Ablation After Initial Long-Term AF Ablation Success
After a 3-month blanking period, 49 (36%) patients had documented arrhythmia recurrence, of which 47 (34%) were symptomatic. Recurrent arrhythmias were AF in 35 (71%) patients, AFL in 9 (18%), and a combination of both in 5 (10%). The median time to recurrence was 13.3 months (5.3-32.5 months). Additional ablation procedures were performed in 19 patients (14%) 14.7 months (6.5-35.5 months) later.
The total number of repeat ablation procedures after initial long-term success was 1 in 118 patients, 2 in 15 patients, and 3 in the remaining 4 patients.
After a median follow-up of 17 months (5-36.9 months) after the last ablation procedure, 103 patients (75%) were arrhythmia free (79 off antiarrhythmics, 24 on antiarrhythmics). Of the patients who did not have any PV reconnections on redo ablation after initial longterm success (n=26), 10 (38%) had arrhythmia recurrence (7 AF, 3 AFL) and 16 (62%) remained free from arrhythmia on follow-up (13 off antiarrhythmics, 3 on antiarrhythmics).
Complications from the repeat ablation procedures (n=160) occurred in 4 patients (2.5%). Two (1.25%) patients had PV stenosis. One of them had severe stenosis of left superior PV requiring stenting and other had severe stenosis of left inferior PV which also required stenting. Pericardial tamponade requiring pericardiocentesis occurred in 1 (0.6%). Local infection (prostatitis) occurred in 1 (0.6%) patient. No deaths occurred as a result of these complications.
DISCUSSION
The current study assessed the electrophysiological findings and repeat ablation procedures outcomes in patients with arrhythmia recurrence after initially achieving long-term success with ≥1 previous AF ablation procedures. AF recurrences despite achieving longterm success (at least 36 months post-ablation) have been reported, 11, 12 yet not well studied in terms of pathophysiology and treatment outcomes. To the best of our knowledge, this is the largest study to-date to evaluate the electrophysiological findings and the outcomes of repeat ablation in this setting.
An important and interesting finding is that in patients with arrhythmia recurrence after long-term success, PV reconnection of at least one of the PVs remains very common (81%), but with lower rates than what had been reported for early recurrences. 5 In our experience, repeat ablations in these patients involve complex ablation strategies aiming at reisolation of the PVs, extension of previous antral ablations, and modification of the atrial substrate, eventually leading to acceptable rates of freedom from atrial tachyarrhythmias.
Our study results shed light on the importance of the substrate-trigger interplay in the pathophysiology of AF recurrence. The long-term success achieved with prior ablation procedures in this patient population implies that effective and durable PV isolation was attained. However, very late recurrences in this setting were still associated with a high prevalence of reconnection along at least one of the previously ablated PVs. The reconnection of PVs despite ensuring proper isolation during initial ablation procedures has been previously described. Although in many cases it could be related to gaps in ablation lines, acute edema, or lack of transmural lesions, PV conduction recovery has been reported after surgical ablations. For instance, a study from our group investigating AF mechanisms in lung transplantation recipients demonstrated evidence of electric conduction recovery after surgical resection and anastomosis of the PVs, which may be considered as the ultimate form of PV isolation. 13 Although PV reconnection has been shown to be the primary electrophysiological finding in early recurrences and repeat ablation with PV reisolation has been shown to be incrementally beneficial, 7 the exact mechanisms of the electric reconnection remain unknown. The timing of PV conduction recovery in the current study's population is also difficult to determine but is likely to have occurred early after the index ablation procedures and it is possible that progression of the substrate occurred over time, eventually leading to recurrences. On the other hand, the observation of high rates of PV reconnection does not imply a cause and effect relationship in the pathophysiology of recurrent arrhythmias. Although reisolation of the PVs was performed whenever reconnection was detected in addition to extension of ablations around the PV antra and substrate modification, there was only a small incremental freedom from AF during follow-up in patients who required reisolation of the PVs versus those who did not. This hypothetically implies that the atrial substrate plays an important role in orchestrating arrhythmia recurrences after initial long-term success. Efforts aiming at better substrate characterization, for example, using cardiac magnetic resonance imaging, may be associated with improved ablation outcomes in this setting. This hypothesis is currently being tested in the ongoing DECAAFII trial (Efficacy of Delayed Enhancement MRI-Guided Ablation Versus Conventional Catheter Ablation of Atrial Fibrillation; URL: http://www. clinicaltrials.gov. Unique identifier: NCT02529319).
Study Limitations
The study has the inherent limitations of observational studies. It was performed retrospectively; however, the identification of the study population and most of data collection was derived from a prospectively maintained registry. The lack of a control group limits the interpretation of the electrophysiological findings in the context of clinical recurrence; however, it is practically challenging to get invasive electrophysiological data in patients without clinical arrhythmia recurrence. Another limitation is that formal substrate assessment using voltage mapping or advanced imaging such as cardiac magnetic resonance imaging was not performed. Nonetheless, after an anatomic-based approach, we were able to achieve good outcomes. It is possible that formal substrate assessment using the above-mentioned methods could have improved the ablation outcomes. AF recurrences were defined based on documentations on ECG or telemonitors done at routine intervals or when triggered by patients' symptoms, hence, asymptomatic AF recurrences may have been missed and that is a common limitation to most AF ablation outcome studies. It would be difficult to ascertain the number of missed events in each subgroup; however, it would be reasonable to assume that both groups would have been equally affected by these events. This group of patients had documented recurrence and was brought to the laboratory for redo primarily because of symptoms. Finally, the study was conducted in a large tertiary care referral center, and AF ablations were performed by experienced operators, which may limit the generalizability of the results to lower volume centers and operators.
Conclusions
PV reconnection is the most common electrophysiological finding in patients with AF recurrence after initial long-term success, but with lower rates than what had been reported for early recurrences. In our experience, repeat ablations in this setting involve complex ablation approaches to reisolate the PVs, extend antral ablations, and modify the atrial substrate and are associated with acceptable success rates. 
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